SCHEMBL6691608

SCHEMBL6691608

O=S(=O)(Nc1cscc1-c1cccnc1)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
GAA P10253 2/20 0.51
MAPT P10636 2/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
RECQL P46063 1/20 0.51
CKS1B P61024 5/20 0.50
SKP2 Q13309 5/20 0.50
MMP2 P08253 2/20 0.49
POLB P06746 1/20 0.49
PTGS2 P35354 1/20 0.49
NAMPT P43490 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
CYP2E1 P05181 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081726 0.88 MEN1 (0.56) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL6612979 0.83 CKS1B (0.47) MEN1KMT2AHTTCKS1BSKP2
SCHEMBL28402292 0.80 NAMPT (0.60) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL28455396 0.79 SLC22A12 (0.67) CKS1BSKP2PTGS2NAMPTCYP3A4
SCHEMBL7076390 0.79 MEN1 (0.51) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL6694347 0.78 CKS1B (0.60) MEN1KMT2AGAAMAPTHTT
SCHEMBL6612943 0.78 MEN1 (0.53) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL6690050 0.77 SLC40A1 (0.49) MEN1KMT2AMAPTMAPK1CKS1B
SCHEMBL2762873 0.76 KDM1A (0.72) MEN1KMT2AMAPTMAPK1POLB
SCHEMBL8871411 0.76 STAT3 (0.52) MEN1KMT2AMAPTPOLBPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 MEN1 770/4885KMT2A 3247/4885GAA 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.